Between cisplatin and carboplatin, which agent causes more myelosuppression?

Carboplatin Causes More Myelosuppression Than Cisplatin

Carboplatin is significantly more myelosuppressive than cisplatin, particularly causing thrombocytopenia, and this is the dose-limiting toxicity for carboplatin. 1

Evidence from Clinical Guidelines

The American Society of Clinical Oncology (ASCO) guidelines explicitly state that carboplatin is more likely to increase myelosuppression and cause thrombocytopenia compared to cisplatin. 1 Multiple meta-analyses and randomized controlled trials consistently demonstrated that carboplatin causes significantly higher rates of thrombocytopenia than cisplatin. 1

In the ASCO guideline for small-cell lung cancer, the evidence shows that carboplatin-based regimens resulted in more myelosuppression, while cisplatin caused more nausea, vomiting, neurotoxicity, and nephrotoxicity. 1

FDA-Approved Drug Label Evidence

The FDA label for carboplatin explicitly identifies bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) as dose-dependent and the dose-limiting toxicity for carboplatin. 2 The label warns that bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. 2

In comparative clinical trials documented in the FDA label:

• Thrombocytopenia <100,000/mm³ occurred in 70% of carboplatin patients versus 29% of cisplatin patients (p<0.001) in the NCIC study 2
• Severe thrombocytopenia <50,000/mm³ occurred in 41% versus 6% (p=0.001) 2
• Leukopenia <2,000/mm³ occurred in 68% versus 52% (p=0.001) 2
• Transfusion requirements were significantly higher with carboplatin (42% versus 31%, p=0.018) 2

Toxicity Profile Differences

Carboplatin's Myelosuppressive Pattern:

• Thrombocytopenia is the predominant and most severe hematologic toxicity 1, 2
• Median nadir occurs at day 21 in patients receiving single-agent carboplatin 2
• Anemia is cumulative and transfusions may be needed during prolonged therapy 2
• Neutropenia and leukopenia are also more common than with cisplatin 2

Cisplatin's Non-Hematologic Toxicity Pattern:

• Cisplatin causes significantly more nephrotoxicity, neurotoxicity, ototoxicity, and nausea/vomiting 1
• Peripheral neuropathy and ototoxicity are characteristic cisplatin toxicities 1
• Renal toxicity is the dose-limiting toxicity for cisplatin, not myelosuppression 3

Clinical Implications

Relative contraindications to carboplatin include baseline thrombocytopenia and bleeding risk due to its myelosuppressive profile. 1 In contrast, relative contraindications to cisplatin include baseline hearing loss, renal insufficiency, congestive heart failure, and conditions limiting intravenous hydration. 1

The pattern of toxicity is so distinct that carboplatin is often substituted for cisplatin in patients with contraindications to cisplatin (such as renal dysfunction), accepting the trade-off of increased myelosuppression for reduced nephrotoxicity and neurotoxicity. 1

Common Pitfall to Avoid

Do not assume equivalent hematologic toxicity between these platinum agents. Carboplatin requires more intensive monitoring of platelet counts and may necessitate dose reductions or transfusion support more frequently than cisplatin. 2 Patients with pre-existing bone marrow compromise or those receiving concurrent myelosuppressive agents require particularly careful monitoring when treated with carboplatin. 2